International Marketing and Sales II – Blog Post by Asrar Qureshi
Dear Colleagues! Today is Pharma Veterans Blog Post #118. Pharma Veterans shares your wealth of knowledge and wisdom with others for the benefit of entire Pharma Community. It aims to recognize and celebrate the Pharma Industry Professionals. Pharma Veterans Blog is published by Asrar Qureshi on WordPress, the top blog site. Please share your stories, ideas and thoughts. Please email to asrar@asrarqureshi.com for publishing your contributions here.
I shall discuss International Marketing & Sales in some detail so
that my readers get a fair idea of this segment of business.
International business is much less understood as compared to domestic
marketing. It is because there is a divide between the two. It is interesting
that people move from domestic to international business but rarely move back.
It is the ‘other side’ from which normally there is no return. There is a large
population in domestic market and a tiny group in international business. The particles
move from higher concentration to lower concentration but cannot come back.
Anyway, this is not really the point of discussion.
I tried to understand the working of international business and talked to
some of the veterans. I am grateful to them for their knowledge sharing. It was
still sketchy though. I had a unique privilege as I dealt with export (international
business) and in-licensing/import both. I got a view of both.
The Pharma World
At Large
The world pharma market has reached over a trillion. About 35% is North America
alone. Around 22% is Western Europe, 10% is China, 9% is Japan, 4% is Russia
and the balance 20% is Rest of World. The distribution of pharma market is not
equitable, but it is in line with inequitable distribution of resources.
From regulatory view, there are highly regulated countries (North
America, Europe, Australia, Japan) which carry the highest standards. Then
there are moderately regulated countries like some parts of middle east and far
east and eastern Europe. Rest of World comprises of least regulated countries. The
highly regulated countries can export to least regulated countries, but the reverse
cannot happen. Pakistan is among least regulated countries and therefore can
only export to similar countries.
Export Regions
for Pakistan Pharma
Following regions have been possible export destinations for Pakistan
Pharma.
·
Close to home, Afghanistan
·
South Asia – Sri Lanka. (Maldives, Nepal, Bhutan are
small and dominated by Indian Pharma. Pharma trade between Bangladesh and
Pakistan could not develop due to political issues. India has highly developed
industry of its own; over 25,000 companies versus 700 in Pakistan)
·
Southeast Asia – Vietnam, Cambodia, Myanmar,
Philippines. (Laos is small; Thailand, Malaysia are not interested; Indonesia
has a developed industry)
·
Central Asia – Uzbekistan, Kyrgyzstan. (Tajikistan,
Turkmenistan are small; Azerbaijan, Kazakhstan are upscale markets)
·
East Africa – Kenya, Tanzania, Uganda, Sudan.
(Ethiopia is difficult; Djibouti is tiny)
·
West Africa – Nigeria, Ghana. (Niger, Chad are
small; Senegal is not interested; Gambia is tiny)
·
South Africa – South Africa is more regulated. (Other
countries are small and fragmented)
·
North Africa – Egypt has its own industry; Libya is not
interested; Algeria, Morocco, Tunisia, Mauritania are pro-Europe.
·
Central Africa – Cameroon may be. Other countries
are small, fragmented and unsafe.
·
Middle East – Yemen was a good destination but is disturbed
now. Saudi Arabia, UAE, Syria, Lebanon, Iran are not interested; Iraq is
disturbed.
·
There are several more countries, in Africa and
elsewhere but establishing and sustaining business there is challenging.
·
Some companies are venturing into eastern Europe
like Ukraine, Belarus and even Russia. We wish them well.
·
Other countries are not favorable due mainly to regulatory
reasons
I had the opportunity to travel to most of the possible destinations and
some more. I researched the markets firsthand and learned about registration
procedures and requirements.
To be continued……
Comments
Post a Comment